Thus, polyI:C treatment might not only target TLR3 in tumour cells and induce an anti-tumour type I interferon-rich environment or tumour apoptosis [11] but will also target the maturation and antigen presentation of DCs specialised in the cross-presentation of tumour-associated antigens. This evidence concerns the gene TLR3 and neoplasm.